Clinical Trial Update: A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation) [Phase 1]

View source ↗

Summary

Phase 1 study to evaluate different doses of BI-1701963 alone and in combination with trametinib in patients with advanced solid tumors that harbor KRAS mutatio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors with Kras Mutation

Drugs mentioned

• BI-1701963 (BI-1701963)
• Trametinib (trametinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Solid Tumors, KRAS Mutation; SOS1 | Phase 1 | Status: ACTIVE_NOT_RECRUITING